Anand Anandkumar

The AMR Industry Alliance brings together over 100 research-based pharmaceutical, generics, biotech and diagnostic companies and associations, to drive and measure the life-sciences’ industry progress to curb #AMR. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Declaration (January 2016) and the Roadmap (September 2016) and measures industry’s progress in the fight against antimicrobial resistance. A first progress report was launched in January 2018, and tracked progress in four different areas (Research and Science, Access, Appropriate Use, and Environment), identify gaps and set targets for the future. The Alliance’s reporting will provide timely and concrete insights to inform decision-making at global level and help to assess what are the key hurdles impeding action, and facilitate collaboration between the public and private sectors: https://www.amrindustryalliance.org/progress-report/. The second progress report will be launched in January 2020.

The AMR Industry Alliance brings together over 100 research-based pharmaceutical, generics, biotech and diagnostic companies and associations, to drive and measure the life-sciences’ industry progress to curb #AMR. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Declaration (January 2016) and the Roadmap (September 2016) and measures industry’s progress in the fight against antimicrobial resistance. A first progress report was launched in January 2018, and tracked progress in four different areas (Research and Science, Access, Appropriate Use, and Environment), identify gaps and set targets for the future. The Alliance’s reporting will provide timely and concrete insights to inform decision-making at global level and help to assess what are the key hurdles impeding action, and facilitate collaboration between the public and private sectors: https://www.amrindustryalliance.org/progress-report/. The second progress report will be launched in January 2020.

Cellworks Group, Inc. is a leader in Precision Drug Development and Personalized Therapy Biosimulation. The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology. Backed by Artiman Ventures, Bering Capital, Sequoia Capital, UnitedHealth Group and Agilent Ventures, Cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers and software technologists working toward a common goal – attacking serious diseases to improve the lives of patients.

Magma Design Automation is now part of Synopsys Inc. Please visit Synopsys'​ company page on LinkedIn http://www.linkedin.com/company/synopsys Synopsys, Inc. (Nasdaq:SNPS) is a world leader in delivering semiconductor design software, intellectual property (IP), design for manufacturing (DFM) solutions and professional services that companies use to design systems-on-chips (SoCs) and electronic systems. The company's products enable semiconductor, manufacturing, computer, communications, consumer electronics and other companies that develop electronic products to improve performance, increase productivity and achieve predictable success from systems to silicon.